Active, not recruitingPhase 3NCT06239480
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Studying Microcystic lymphatic malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Palvella Therapeutics, Inc.
- Principal Investigator
- Joyce Teng, MDStanford University
- Intervention
- QTORIN 3.9% Rapamycin Anhydrous Gel(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2024 – 2026
Study locations (15)
- Children's Hospital of Orange County, Irvine, California, United States
- Stanford University, Palo Alto, California, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Minnesota Clinical Study Center, New Brighton, Minnesota, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Vascular Birthmark Institute, New York, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Vanderbilt Children's Hospital, Nashville, Tennessee, United States
- University of Texas, Dell Children's, Austin, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
- University of Utah Health, Salt Lake City, Utah, United States
Collaborators
FDA Office of Orphan Products Development
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06239480 on ClinicalTrials.gov